Aspen looks to ward off Endurance with poison pill
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • X
  • LinkedIn
  • Email
  • Free trial
  • Log in

Aspen looks to ward off Endurance with poison pill

17 April 2014
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • X
  • LinkedIn
  • Email

Two days after rejecting Endurance's $3.2bn hostile takeover bid, Aspen has turned to a so-called 'poison pill' strategy that attempts to make its stock less attractive to a buyer.

Subscribers, log in here:

Fuel a smarter strategy with our actionable market intelligence

      • Gain a competitive edge and accelerate decision-making
      • Be empowered by insights that transform confusion to clarity
      • Uncover growth opportunities and prepare for potential threats
      • Fuel a smarter strategy for business growth
Request a free trial Already a subscriber? Log in now

Topics

News M&A
Gift this article